Literature DB >> 20678370

Seizures in cerebral arteriovenous malformations: type, clinical course, and medical management.

A Osipov1, H C Koennecke, A Hartmann, W L Young, J Pile-Spellman, L Hacein-Bey, J P Mohr, H Mast.   

Abstract

SUMMARY: We investigated the type and early clinical course of seizure disorders in cerebral arteriovenous malformations (AVMs). Decisions on invasive treatment for AVMs depend on detailed knowledge of the natural course and prognosis of neurologic sequelae. Among 328 patients of a prospective cerebral AVM databank 92 (28%) presented with seizures unrelated to haemorrhage. Under a median observation time of 2.2 years (mean 3.8 years) the 92 patients received 454 follow-up examinations (median time interval 4.6 months). All patients were treated with anticonvulsant medication. During the observation period sixty (65%) patients received staged endovascular glue embolisation. The effect of staged embolisation on seizure recurrence was tested univariately by comparing patients undergoing embolisation versus those without endovascular treatment. At the time of enrolment in the database, elementary (motor or sensory) and partial complex seizures were described in twenty (22 %) and one (1%) patients, respectively. Generalized seizures without focal initiation were reported in sixty (65%) and with focal initiation in 11 (12%) patients. 57 (62%) cases had suffered a seizure as a first single event, ten (11%) had weekly, 17 (19%) monthly, and eight (9%) patients had seizures once per year. In the following clinical course, complete cessation of seizure activity was seen in 69 (75%). Ten (11%) patients continued to have seizures at a rate of once per year or less. 13 (14%) cases continued to have weekly to monthly events with only four (4%) of them showing (monthly) grand mal. An early beneficial effect of staged embolisation on seizure recurrence was not observed. Seizure disorders in cerebral AVMs show a benign early course, leaving few patients with insufficient seizure control. The differential longterm effect of invasive AVM treatment on seizure control should be subject to clinical trials.

Entities:  

Year:  2001        PMID: 20678370     DOI: 10.1177/159101999700300104

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  6 in total

1.  Seizures after Onyx embolization for the treatment of cerebral arteriovenous malformation.

Authors:  K de Los Reyes; A Patel; A Doshi; N Egorova; F Panov; J B Bederson; J A Frontera
Journal:  Interv Neuroradiol       Date:  2011-10-17       Impact factor: 1.610

Review 2.  Diagnosis and treatment of arteriovenous malformations.

Authors:  J P Mohr; J Kejda-Scharler; J Pile-Spellman
Journal:  Curr Neurol Neurosci Rep       Date:  2013-02       Impact factor: 5.081

Review 3.  Treatment of arteriovenous malformations of the brain.

Authors:  Andreas Hartmann; Henning Mast; Jae H Choi; Christian Stapf; Jay P Mohr
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

4.  Accuracy of susceptibility-weighted imaging for the detection of arteriovenous shunting in vascular malformations of the brain.

Authors:  Bharathi D Jagadeesan; Josser E Delgado Almandoz; Christopher J Moran; Tammie L S Benzinger
Journal:  Stroke       Date:  2010-11-18       Impact factor: 7.914

Review 5.  Medical vs. invasive therapy in AVM-related epilepsy: Systematic review and meta-analysis.

Authors:  Colin B Josephson; Khara Sauro; Samuel Wiebe; Fiona Clement; Nathalie Jette
Journal:  Neurology       Date:  2015-12-07       Impact factor: 9.910

Review 6.  Cerebral arteriovenous malformations: evaluation and management.

Authors:  Norman Ajiboye; Nohra Chalouhi; Robert M Starke; Mario Zanaty; Rodney Bell
Journal:  ScientificWorldJournal       Date:  2014-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.